Open-label Safety Study in Adults With ADHD

Adult Attention Deficit Hyperactivity Disorder Clinical Trial

Official title:
A Phase 3, 12-Month, Multicenter, Open-label, Flexibly-dosed, Safety Study of SEP 225289 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Status Completed

Clinical Trial Summary

To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with Attention Deficit Hyperactivity Disorder (ADHD)

Clinical Trial Description

To evaluate the long-term safety and tolerability of SEP 225289 in adult subjects with ADHD by the incidence of adverse events (AEs; or serious AEs), AEs (or SAEs) leading to discontinuation ;

Study Design

Related Conditions & MeSH terms

Adult Attention Deficit Hyperactivity Disorder
Attention Deficit Disorder with Hyperactivity
Hyperkinesis

Clinical Trial Details

NCT number	NCT02160262
Study type	Interventional
Source	Sunovion
Contact
Status	Completed
Phase	Phase 3
Start date	June 2014
Completion date	May 2016

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06000501` - Duration and Efficacy of Azstarys on Adult ADHD Symptoms and Executive Function in Early Evening	Phase 4
Completed	`NCT03721588` - Clinical and Suicidal Features of Urban, Turkish Middle Age Depressive Patients With Comorbid ADHD
Completed	`NCT03324581` - The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder	Phase 2
Active, not recruiting	`NCT06221930` - Researching the Effectiveness of Attexis, a Digital Health Application for Adults With Attention Deficit Hyperactivity Disorder	N/A
Completed	`NCT02276209` - Dasotraline Adult ADHD Study	Phase 3
Completed	`NCT01692782` - Adult Attention Deficit Hyperactivity Disorder	Phase 2
Completed	`NCT01798381` - Essential Fatty Acids in Adult ADHD	Phase 3
Completed	`NCT00553319` - Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence	Phase 2/Phase 3